ABBV/Roche—Venetoclax NDA in second-line CLL accepted by FDA with priority review; corresponding MAA validated by EMA: http://finance.yahoo.com/news/u-european-regulators-accept-applications-133000651.html The PDUFA date should be on or about 7/11/16.